Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: results from a meta-analysis of large animal studies

The incidence of severe ischemic heart disease caused by coronary obstruction has progressively increased. Alternative forms of treatment have been studied in an attempt to regenerate myocardial tissue, induce angiogenesis, and improve clinical conditions. In this context, cell therapy has emerged as a promising alternative using cells with regenerative potential, focusing on the release of paracrine and autocrine factors that contribute to cell survival, angiogenesis, and tissue remodeling. Evidence of the safety, feasibility, and potential effectiveness of cell therapy has emerged from several clinical trials using different lineages of adult stem cells. The clinical benefit, however, is not yet well established. In this review, we discuss the therapeutic potential of cell therapy in terms of regenerative and angiogenic capacity after myocardial ischemia. In addition, we addressed nonpharmacological interventions that may influence this therapeutic practice, such as diet and physical training. This review brings together current data on pharmacological and nonpharmacological approaches to improve cell homing and cardiac repair.

Download Full-text

1P-0098 Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: A meta-analysis

Atherosclerosis Supplements ◽

10.1016/s1567-5688(03)90173-5 ◽

2003 ◽

Vol 4 (2) ◽

pp. 41

Author(s):

A. Sethi ◽

B.G. Nordestgaard ◽

A. Tybjærg-Hansen

Keyword(s):

Heart Disease ◽

Gene Polymorphism ◽

Ischemic Heart Disease ◽

Meta Analysis ◽

Ischemic Heart ◽

Angiotensinogen Gene

Download Full-text

Modern statin therapy in clinical practice: The lower the better

Srpski arhiv za celokupno lekarstvo ◽

10.2298/sarh1302104s ◽

2013 ◽

Vol 141 (1-2) ◽

pp. 104-106 ◽

Cited By ~ 1

Author(s):

Edita Stokic

Keyword(s):

Heart Disease ◽

Cardiovascular Risk ◽

Ischemic Heart Disease ◽

Statin Therapy ◽

Meta Analysis ◽

Ischemic Heart ◽

Mortality And Morbidity ◽

Increased Risk ◽

Coronary Events ◽

Risk Treatment

Lipid and lipoprotein disorders are well known risk factors for atherosclerosis and its complications. The level of atherogenic LDL-cholesterol (LDL-C) is directly related to an increased risk of occurrence and progression of ischemic heart disease. Epidemiological and clinical studies have shown that the use of statin therapy to decrease LDL-C can significantly reduce the incidence of mortality, major coronary events and the need for revascularization procedures in the different groups of patients. The findings of a large meta-analysis conducted by the Cholesterol Treatment Trialists? (CTT) collaborators showed that every 1.0 mmol/l reduction of atherogenic LDL-C is associated with a 22% reduction in cardiovascular diseases mortality and morbidity. However, despite the impressive results of the benefits of statin therapy, the EUROASPIRE study showed that about 50% of patients with ischemic heart disease did not achieve target LDL-C levels. According to the new ESC/EAS Guidelines for the Management of Dyslipidaemias in patients with a very high cardiovascular risk, treatment goal should be to decrease LDL-C below 1.8 mmol/l or ?50% of initial values. In the majority of patients that can be achieved by statin therapy. For this reason an adequate choice of statins is of crucial importance, whereby the needed reduction in atherogenic LDL-C, after the identification of its target level based on the assessment of total cardiovascular risk, can be achieved.

Download Full-text

Mobile Phone Technologies in the Management of Ischemic Heart Disease, Heart Failure, and Hypertension: Systematic Review and Meta-Analysis

JMIR mhealth and uhealth ◽

10.2196/16695 ◽

2020 ◽

Vol 8 (7) ◽

pp. e16695 ◽

Cited By ~ 1

Author(s):

Praveen Indraratna ◽

Daniel Tardo ◽

Jennifer Yu ◽

Kim Delbaere ◽

Matthew Brodie ◽

...

Keyword(s):

Heart Failure ◽

Systematic Review ◽

Heart Disease ◽

Ischemic Heart Disease ◽

Mobile Phone ◽

Meta Analysis ◽

Random Effect ◽

Random Effect Model ◽

Ischemic Heart ◽

Valuable Adjunct

Background Cardiovascular disease (CVD) remains the leading cause of death worldwide. Mobile phones have become ubiquitous in most developed societies. Smartphone apps, telemonitoring, and clinician-driven SMS allow for novel opportunities and methods in managing chronic CVD, such as ischemic heart disease, heart failure, and hypertension, and in the conduct and support of cardiac rehabilitation. Objective A systematic review was conducted using seven electronic databases, identifying all relevant randomized control trials (RCTs) featuring a mobile phone intervention (MPI) used in the management of chronic CVD. Outcomes assessed included mortality, hospitalizations, blood pressure (BP), and BMI. Methods Electronic data searches were performed using seven databases from January 2000 to June 2019. Relevant articles were reviewed and analyzed. Meta-analysis was performed using standard techniques. The odds ratio (OR) was used as a summary statistic for dichotomous variables. A random effect model was used. Results A total of 26 RCTs including 6713 patients were identified and are described in this review, and 12 RCTs were included in the meta-analysis. In patients with heart failure, MPIs were associated with a significantly lower rate of hospitalizations (244/792, 30.8% vs 287/803, 35.7%; n=1595; OR 0.77, 95% CI 0.62 to 0.97; P=.03; I2=0%). In patients with hypertension, patients exposed to MPIs had a significantly lower systolic BP (mean difference 4.3 mm Hg; 95% CI −7.8 to −0.78 mm Hg; n=2023; P=.02). Conclusions The available data suggest that MPIs may have a role as a valuable adjunct in the management of chronic CVD.

Download Full-text

Bone Marrow Cell Therapy for Ischemic Heart Disease and the Role of Cardiac Imaging in Evaluation of Outcomes

Stem Cell Biology and Regenerative Medicine - Imaging in Stem Cell Transplant and Cell-based Therapy ◽

10.1007/978-3-319-51833-6_9 ◽

2017 ◽

pp. 133-152 ◽

Cited By ~ 1

Author(s):

Anweshan Samanta ◽

Muhammad R. Afzal ◽

Buddhadeb Dawn

Keyword(s):

Bone Marrow ◽

Heart Disease ◽

Cell Therapy ◽

Ischemic Heart Disease ◽

Bone Marrow Cell ◽

Cardiac Imaging ◽

Marrow Cell ◽

Ischemic Heart ◽

Bone Marrow Cell Therapy

Download Full-text

New strategies for improving stem cell therapy in ischemic heart disease

Heart Failure Reviews ◽

10.1007/s10741-016-9576-1 ◽

2016 ◽

Vol 21 (6) ◽

pp. 737-752 ◽

Cited By ~ 24

Author(s):

Peisen Huang ◽

Xiaqiu Tian ◽

Qing Li ◽

Yuejin Yang

Keyword(s):

Stem Cell ◽

Heart Disease ◽

Cell Therapy ◽

Ischemic Heart Disease ◽

Stem Cell Therapy ◽

Ischemic Heart ◽

New Strategies

Download Full-text

Nonthyroidal Illness Syndrome and Hypothyroidism in Ischemic Heart Disease Population: A Systematic Review and Meta-Analysis

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/clinem/dgaa310 ◽

2020 ◽

Vol 105 (8) ◽

pp. 2830-2845

Author(s):

Chun-Yu Chang ◽

Yung-Jiun Chien ◽

Po-Chen Lin ◽

Chien-Sheng Chen ◽

Meng-Yu Wu

Keyword(s):

Heart Disease ◽

Ischemic Heart Disease ◽

Meta Analysis ◽

Ischemic Heart ◽

Cochrane Library ◽

Future Research ◽

Sufficient Information ◽

Cardiac Events ◽

Coronary Syndrome ◽

All Cause Mortality

Abstract Context The association of non-thyroidal illness syndrome (NTIS) and hypothyroidism with the prognosis in ischemic heart disease (IHD) population is inconclusive. Objective We aimed to evaluate the influence of NTIS and hypothyroidism on all-cause mortality and major adverse cardiac events (MACE) in IHD population. Data Sources We searched PubMed, EMBASE, Scopus, Web of Science, and Cochrane Library from inception through February 17, 2020. Study Selection Original articles enrolling IHD patients, comparing all-cause mortality and MACE of NTIS and hypothyroidism with those of euthyroidism, and providing sufficient information for meta-analysis were considered eligible. Data Extraction Relevant information and numerical data were extracted for methodological assessment and meta-analysis. Data Synthesis Twenty-three studies were included. The IHD population with NTIS was associated with higher risk of all-cause mortality (hazard ratio [HR] = 2.61; 95% confidence interval [CI] = 1.89-3.59) and MACE (HR = 2.22; 95% CI = 1.71-2.89) than that without. In addition, the IHD population with hypothyroidism was also associated with higher risk of all-cause mortality (HR = 1.47; 95% CI = 1.10-1.97) and MACE (HR = 1.53; 95% CI = 1.19-1.97) than that without. In the subgroup analysis, the acute coronary syndrome (ACS) subpopulation with NTIS was associated with higher risk of all-cause mortality (HR = 3.30; 95% CI = 2.43-4.48) and MACE (HR = 2.19; 95% CI = 1.45-3.30). The ACS subpopulation with hypothyroidism was also associated with higher risk of all-cause mortality (HR = 1.67; 95% CI = 1.17-2.39). Conclusions The IHD population with concomitant NTIS or hypothyroidism was associated with higher risk of all-cause mortality and MACE. Future research is required to provide evidence of the causal relationship and to elucidate whether normalizing thyroid function parameters can improve prognosis.

Download Full-text